These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 26039179)

  • 1. Loteprednol etabonate in the treatment of allergic conjunctivitis: a meta-analysis.
    Wu LQ; Chen X; Lou H; Cheng JW; Wei RL
    Curr Med Res Opin; 2015 Aug; 31(8):1509-18. PubMed ID: 26039179
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of the clinical efficacy and tolerability of olopatadine hydrochloride 0.1% ophthalmic solution and loteprednol etabonate 0.2% ophthalmic suspension in the conjunctival allergen challenge model.
    Berdy GJ; Stoppel JO; Epstein AB
    Clin Ther; 2002 Jun; 24(6):918-29. PubMed ID: 12117082
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Loteprednol etabonate suspension 0.2% administered QID compared with olopatadine solution 0.1% administered BID in the treatment of seasonal allergic conjunctivitis: a multicenter, randomized, investigator-masked, parallel group study in Chinese patients.
    Gong L; Sun X; Qu J; Wang L; Zhang M; Zhang H; Wang L; Gu Y; Elion-Mboussa A; Roy L; Zhu B
    Clin Ther; 2012 Jun; 34(6):1259-1272.e1. PubMed ID: 22627057
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The conjunctival provocation test model of ocular allergy: utility for assessment of an ocular corticosteroid, loteprednol etabonate.
    Abelson M; Howes J; George M
    J Ocul Pharmacol Ther; 1998 Dec; 14(6):533-42. PubMed ID: 9867336
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A double-masked, placebo-controlled evaluation of the efficacy and safety of loteprednol etabonate in the treatment of giant papillary conjunctivitis.
    Asbell P; Howes J
    CLAO J; 1997 Jan; 23(1):31-6. PubMed ID: 9001768
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomized, double-masked, placebo-controlled parallel study of 0.2% loteprednol etabonate in patients with seasonal allergic conjunctivitis.
    Dell SJ; Lowry GM; Northcutt JA; Howes J; Novack GD; Hart K
    J Allergy Clin Immunol; 1998 Aug; 102(2):251-5. PubMed ID: 9723669
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of olopatadine hydrochloride 0.1%, emedastine difumarate 0.05%, and loteprednol etabonate 0.5% for Chinese children with seasonal allergic conjunctivitis: a randomized vehicle-controlled study.
    Liu RF; Wu XX; Wang X; Gao J; Zhou J; Zhao Q
    Int Forum Allergy Rhinol; 2017 Apr; 7(4):393-398. PubMed ID: 27869354
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomized, double-masked, placebo-controlled parallel study of loteprednol etabonate 0.2% in patients with seasonal allergic conjunctivitis.
    Shulman DG; Lothringer LL; Rubin JM; Briggs RB; Howes J; Novack GD; Hart K
    Ophthalmology; 1999 Feb; 106(2):362-9. PubMed ID: 9951491
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of the Topical Ophthalmic Corticosteroid Loteprednol Etabonate on Intraocular Pressure.
    Sheppard JD; Comstock TL; Cavet ME
    Adv Ther; 2016 Apr; 33(4):532-52. PubMed ID: 26984315
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A controlled evaluation of the efficacy and safety of loteprednol etabonate in the prophylactic treatment of seasonal allergic conjunctivitis. Loteprednol Allergic Conjunctivitis Study Group.
    Dell SJ; Shulman DG; Lowry GM; Howes J
    Am J Ophthalmol; 1997 Jun; 123(6):791-7. PubMed ID: 9535623
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A double-masked, placebo-controlled evaluation of the efficacy and safety of loteprednol etabonate in the treatment of giant papillary conjunctivitis. The Loteprednol Etabonate Giant Papillary Conjunctivitis Study Group I.
    Friedlaender MH; Howes J
    Am J Ophthalmol; 1997 Apr; 123(4):455-64. PubMed ID: 9124242
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Loteprednol Etabonate 0.5% Gel Vs. Prednisolone Acetate 1% Solution After Descemet Membrane Endothelial Keratoplasty: Prospective Randomized Trial.
    Price MO; Feng MT; Scanameo A; Price FW
    Cornea; 2015 Aug; 34(8):853-8. PubMed ID: 26020827
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Topical Olopatadine in the Treatment of Allergic Conjunctivitis: A Systematic Review and Meta-analysis.
    Kam KW; Chen LJ; Wat N; Young AL
    Ocul Immunol Inflamm; 2017 Oct; 25(5):663-677. PubMed ID: 27192186
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Loteprednol etabonate for inflammatory conditions of the anterior segment of the eye: twenty years of clinical experience with a retrometabolically designed corticosteroid.
    Comstock TL; Sheppard JD
    Expert Opin Pharmacother; 2018 Mar; 19(4):337-353. PubMed ID: 29430976
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term safety of loteprednol etabonate 0.2% in the treatment of seasonal and perennial allergic conjunctivitis.
    Ilyas H; Slonim CB; Braswell GR; Favetta JR; Schulman M
    Eye Contact Lens; 2004 Jan; 30(1):10-3. PubMed ID: 14722462
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and tolerability of loteprednol etabonate 0.5% and tobramycin 0.3% ophthalmic suspension in pediatric subjects.
    Comstock TL; Paterno MR; Bateman KM; Decory HH; Gearinger M
    Paediatr Drugs; 2012 Apr; 14(2):119-30. PubMed ID: 22292487
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and efficacy of loteprednol etabonate for treatment of papillae in contact lens-associated giant papillary conjunctivitis.
    Bartlett JD; Howes JF; Ghormley NR; Amos JF; Laibovitz R; Horwitz B
    Curr Eye Res; 1993 Apr; 12(4):313-21. PubMed ID: 8319490
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Topical loteprednol etabonate 0.5 % for treatment of vernal keratoconjunctivitis: efficacy and safety.
    Oner V; Türkcü FM; Taş M; Alakuş MF; Işcan Y
    Jpn J Ophthalmol; 2012 Jul; 56(4):312-8. PubMed ID: 22622345
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and Safety of Loteprednol 0.5% and Fluorometholone 0.1% After Strabismus Surgery in Children.
    Yoo YJ; Yang HK; Hwang JM
    J Ocul Pharmacol Ther; 2018; 34(6):468-476. PubMed ID: 29958057
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Submicron loteprednol etabonate ophthalmic gel 0.38% for the treatment of inflammation and pain after cataract surgery.
    Fong R; Silverstein BE; Peace JH; Williams JI; Vittitow JL
    J Cataract Refract Surg; 2018 Oct; 44(10):1220-1229. PubMed ID: 30193927
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.